Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKY-0515 Open Label Extension in Huntington's Disease
NCT07537075Phase 3Enrolling by invitation
- Sponsor
- Skyhawk Therapeutics
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of SKY-0515 in Huntington's disease (HD), sponsored by Skyhawk Therapeutics. Started Apr 2026; status: enrolling by invitation.
02
Drugs
SKY-0515
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT07537075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537075.